Semaglutide
More actions
Experience
Log in to add your own experience.
Problems
Titration strategies
→ 0.5 mg SC weekly × ≥4 weeks → 1 mg SC weekly × ≥4 weeks if further glycemic control needed → 2 mg SC weekly (max) if needed[1]
Slower titration is reasonable in any patient with significant GI symptoms, holding at a tolerated dose for 8–12 weeks before advancing is standard practice.Effects
Subjective effects vary considerably with dose and titration speed but reliably include:
- Early satiety, meals feel "complete" at a fraction of prior intake[4]
- Food noise quieting, the most commonly volunteered subjective change. Patients report that intrusive food-related thoughts simply stop.[citation needed]
- Reduced alcohol craving, corroborated by observational and small RCT data; mechanism likely shared with food reward circuitry[8]
- Nausea, dose-dependent, worst in first 1–2 weeks of any new dose level[1]
- Constipation or diarrhea (variable, can alternate)[1]
- Sulfurous eructation (a small but very real subgroup)[citation needed]
- Reduced taste preference for fatty / sweet foods in many users[citation needed]
Pharmacokinetics
Chemistry. 31-amino-acid acylated peptide analog of human GLP-1 (7–37), with Aib substitution at position 8 (blocks DPP-4 cleavage) and a C18 fatty diacid linked via γGlu-2×OEG spacer at Lys26 (drives albumin binding → ~165 h half-life)[5]
Acylation with a C18 fatty diacid drives non-covalent binding to serum albumin, slowing renal clearance and DPP-4 access. The Aib8 substitution renders the peptide DPP-4-resistant. Resulting terminal half-life ~165 h means once-weekly subcutaneous dosing produces near-steady-state plasma levels.[5]
Oral semaglutide (Rybelsus) is co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), a permeation enhancer that transiently raises gastric pH and protects the peptide locally, yielding ~0.4–1% bioavailability, which is sufficient at 14 mg daily to match Ozempic 0.5 mg weekly for glycemic effect (but not for weight loss).[3][9] Strict fasting administration is mandatory; any concurrent food or beverage destroys absorption.[3]
Predominantly catabolic clearance via proteolysis; renal and hepatic impairment do not require dose adjustment.[1] No CYP-mediated metabolism, so the interaction profile is dominated by gastric emptying effects on other oral medicines, not pharmacokinetic competition.[1]Pharmacodynamics
Receptor pharmacology. Selective long-acting agonist of the GLP-1 receptor (class B GPCR). Produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression, and direct cardiovascular and renal protective effects.[10]
At maintenance doses semaglutide produces:
- HbA1c reduction of ~1.5–2.0 percentage points (Ozempic 1 mg)[11]
- Weight loss of ~6 kg (Ozempic 1 mg, T2DM)[11] to ~14.9% body weight (Wegovy 2.4 mg, obesity without T2DM, STEP-1)[4]
- Systolic BP reduction of ~5 mmHg[6]
- Modest LDL-C reduction, larger triglyceride reduction[citation needed]
- 20% relative risk reduction in MACE in obesity without T2DM (SELECT)[6]
- 24% relative risk reduction in kidney + CV composite in T2DM + CKD (FLOW)[12]
Interactions
Pregnancy and lactation
Category formerly X-equivalent; current FDA labeling: avoid in pregnancy.[1] Animal embryofetal toxicity is well-documented.[1] Because the half-life is ~1 week, current guidance is to discontinue at least 2 months before any planned conception.[1]
Postpartum: not recommended during breastfeeding pending more data; small molecule transfer to milk is unlikely given peptide structure but not formally characterized.[citation needed]
Importantly: semaglutide is not a contraceptive, and the medicine may restore ovulation in patients with PCOS or obesity-associated anovulation.[citation needed] Patients of childbearing potential should be counseled about contraception before starting.Monitoring
- Baseline: HbA1c, weight, BP, renal function, lipid panel, ALT/AST (especially for MASH problem)
- Personal or family history of MTC or MEN2, contraindicated, do not start[1]
- Every 3 months for first year: HbA1c, weight, GI tolerability, signs of pancreatitis or gallbladder disease
- Annual: renal function, lipids
- Pre-procedure: hold weekly dose ≥7 days before any planned anesthesia (per ASA 2024 guidance) due to delayed gastric emptying / aspiration risk[13]
Patient counseling
- Slow titration is non-negotiable for tolerability. Patients who insist on faster ramps usually quit from GI side effects.
- Inject SC in abdomen, thigh, or upper arm; rotate sites. Pen is single-patient, multi-dose.[1]
- GI side effects almost always peak in first 2–4 weeks of any new dose level, then attenuate.[1]
- Eat smaller portions earlier in the day. Plate sizes will feel comically large after a few weeks, that is the medicine working, not a problem to fix.
- Hydrate aggressively (volume depletion → AKI is a real risk).[1]
- Resistance training during weight loss protects lean mass and is strongly encouraged.[citation needed]
- If a weekly dose is missed: take within 5 days; if >5 days, skip and resume on the next regular day.[1]
- Avoid alcohol during titration weeks (compounds nausea).
- Pregnancy planning: stop ≥2 months before trying to conceive.[1]
- Surgery: tell every anesthesiologist and surgeon you are on a weekly GLP-1 RA. Hold dose 7 days pre-op.[13]
Relevant anecdote
0 0 0 0
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
See also
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 US FDA. Ozempic (semaglutide) prescribing information. Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s019lbl.pdf
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 US FDA. Wegovy (semaglutide) prescribing information. Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 US FDA. Rybelsus (semaglutide) prescribing information. Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
- ↑ 4.0 4.1 4.2 Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM 384:989. doi:10.1056/NEJMoa2032183
- ↑ 5.0 5.1 5.2 5.3 Lau J, Bloch P, Schäffer L et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58(18):7370–80. doi:10.1021/acs.jmedchem.5b00726
- ↑ 6.0 6.1 6.2 Lincoff AM et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM 389:2221–32. doi:10.1056/NEJMoa2307563
- ↑ Newsome PN et al. (2025). Semaglutide in MASH (ESSENCE). FDA approval basis. [citation needed]
- ↑ Wang W, Volkow ND, Berger NA et al. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun 15:4548. doi:10.1038/s41467-024-48780-6
- ↑ Buckley ST, Bækdal TA, Vegge A et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 10(467):eaar7047. doi:10.1126/scitranslmed.aar7047
- ↑ Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351. doi:10.1016/j.molmet.2021.101351
- ↑ 11.0 11.1 Marso SP et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). NEJM 375:1834–44. doi:10.1056/NEJMoa1607141
- ↑ Perkovic V et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). NEJM 391:109. doi:10.1056/NEJMoa2403347
- ↑ 13.0 13.1 Kindel TL et al. (2024). Perioperative GLP-1 receptor agonist safety guidance. Surg Obes Relat Dis 20(12):1183–8.